Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares ...

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its ...

Novo Nordisk's obesity drug CagriSema failed to outperform Eli Lilly's Mounjaro in the latest trial, causing a dip in Novo's ...

Morgan Stanley analyst Terence Flynn notes that Novo Nordisk (NVO) reported CagriSema Phase 3 data in type two diabetes demonstrating weight ...

Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...

Novo Nordisk said CagriSema appeared to have a safe and well-tolerated profile in the latest trial. The most common adverse events were gastrointestinal, and the vast majority were mild to moderate ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...

Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...

CagriSema, which is a combination of cagrilintide 2.4-milligram and semaglutide 2.4-mg doses, is being developed so people have a better choice for a weight-loss drug when the patents on Ozempic and ...

Novo Nordisk’s stock has dropped around 6.6% in premarket trading Monday following the release of its latest clinical trial data for CagriSema, a treatment for adults with obesity or overweight and ...

Novo Nordisk A/S shares plunged the most since December after another disappointment for the drugmaker’s next-generation shot ...

Here are the most important news items that investors need to start their trading day: ...